Surge Therapeutics Raises $26M Series A Financing To Accelerate Development Of Intraoperative Immunotherapy To Improve Survival Outcomes Post-Surgery
Amount Raised
$26 Million
Round Type
Series A
CambridgeBiotechnologyHealth CareTherapeuticsDescription
SURGE Therapeutics (SURGE) today announced the completion of a $26 million Series A financing led by Camford Capital, with participation from Khosla Ventures, Intuitive Ventures, Pitango HealthTech, 8VC, Alumni Ventures, and the Cancer Research Institute. The funds will be used to accelerate development of the SURGETM intraoperative immunotherapy approach, expand the team, and initiate clinical trials for its injectable biodegradable hydrogel.
Quick answer
SURGE Therapeutics raised $26 Million in a Series A round, dated October 17, 2022. SURGE Therapeutics is based in Cambridge, Maryland, United States.
- How much did SURGE Therapeutics raise?
- SURGE Therapeutics raised $26 Million in a Series A round on October 17, 2022.
- What does SURGE Therapeutics do?
- SURGE seeks to dramatically improve cancer patient survival by disrupting how, when, and where cancer immunotherapy is deployed -- focusing 100% of the effective dose at the right place and at the right time.
- Where is SURGE Therapeutics based and how big is it?
- SURGE Therapeutics is based in Cambridge, Maryland, United States.
- Who are the decision-makers at SURGE Therapeutics?
- Fundz holds 1 contact at SURGE Therapeutics, including the CEO. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Therapeutics and Biotechnology around the same time
Companies in the same sectors as SURGE Therapeutics that raised within 45 days of this round, from Fundz verified event records.
- RE-VANA THERAPEUTICS raised $12M (Series A) on November 30, 2022.
- Nectin Therapeutics raised an undisclosed amount (Series A) on November 30, 2022.
- iECURE raised $65M (Funding Round) on November 30, 2022.
- Escient Pharmaceuticals raised $120M (Series C) on November 28, 2022.
- Parabilis Medicines raised $178M (Series D) on November 21, 2022.
- Opna Bio raised $38M (Series A) on November 21, 2022.
Who to call at SURGE Therapeutics, and when
A new round usually means SURGE Therapeutics is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day SURGE Therapeutics raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at SURGE Therapeutics, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at SURGE Therapeutics. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment SURGE Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Funding Insights
What this usually meansSURGE Therapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.